	US 12,312,384 B2
	Modified meningococcal fHbp polypeptides
Maria Scarselli, Siena (IT); and Daniele Veggi, Siena (IT)
Assigned to GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
Filed by GLAXOSMITHKLINE BIOLOGICALS SA, Rixensart (BE)
Filed on Jun. 2, 2023, as Appl. No. 18/328,162.
Application 18/328,162 is a division of application No. 17/265,610, granted, now 11,708,394, previously published as PCT/EP2019/071410, filed on Aug. 9, 2019.
Claims priority of application No. 18188321 (EP), filed on Aug. 9, 2018.
Prior Publication US 2024/0132550 A1, Apr. 25, 2024 Prior Publication US 2024/0228551 A9, Jul. 11, 2024
Int. Cl. C07K 14/22 (2006.01); A61K 39/095 (2006.01); A61P 31/04 (2006.01)

CPC C07K 14/22 (2013.01) [A61K 39/095 (2013.01); A61P 31/04 (2018.01); C07K 2319/00 (2013.01)]

12 Claims

1. A fusion polypeptide comprising variant meningococcal factor H binding protein (fHbp) polypeptides:

(a) wherein the variant meningococcal fHbp polypeptides include v1, v2 and v3 meningococcal fHbp polypeptides,

(b) wherein the variant meningococcal fHbp polypeptides are in the order v2-v3-v1 from N- to C-terminus,

(c) wherein the v1 meningococcal fHbp polypeptide is a mutant v1.13 meningococcal fHbp polypeptide comprising an amino acid sequence having at least 80% sequence identity to SEQ ID NO: 2, and

(d) wherein the amino acid sequence of the mutant v1.13 meningococcal fHbp polypeptide includes substitution mutations S216R and E211A relative to SEQ ID NO: 2.